Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)
Steven E. Nissen, Kathy Wolski, Gerald F. Watts, et al.
JAMA (2024) Vol. 331, Iss. 18, pp. 1534-1534
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
Steven E. Nissen, Qiuqing Wang, Stephen J. Nicholls, et al.
JAMA (2024)
Closed Access | Times Cited: 13
Oral Muvalaplin for Lowering of Lipoprotein(a)
Stephen J. Nicholls, Wei Ni, Grace M. Rhodes, et al.
JAMA (2024)
Closed Access | Times Cited: 9
Association Between Lipoprotein (a) Levels and Coronary Artery Disease (CAD) Among Patients With or Without CAD Family History
Hayato Tada, Nobuko Kojima, Kan Yamagami, et al.
Journal of Lipid and Atherosclerosis (2025) Vol. 14, Iss. 1, pp. 120-120
Open Access
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Maud Ahmad, Robert A. Hegele
Molecular Diagnosis & Therapy (2025)
Open Access
Outcome Measures for Randomised Clinical Trials and Multicentre Observational Studies of Cardiovascular Diseases Published in Major Clinical Journals: Systematic Review and Evidence Mapping
Asad Bhatty, Chris Wilkinson, Suleman Aktaa, et al.
(2025)
Closed Access
Current Clinical Trials for Treating Elevated Lipoprotein(a)
Christian David Vega Reyes, Rishi Rikhi, Sean Doherty, et al.
Current Cardiovascular Risk Reports (2025) Vol. 19, Iss. 1
Closed Access
Genetic Association of Circulating Lipids and Lipid-lowering Drug Targets with Vascular Calcification
Pengfei Zhang, Wenting Wang, Xu Qian, et al.
Atherosclerosis (2025) Vol. 403, pp. 119136-119136
Closed Access
siRNA-based Delivery Systems: Technologies, Carriers, Applications, and Approved Products
Parisa Ghasemiyeh, Soliman Mohammadi‐Samani
European Journal of Pharmacology (2025), pp. 177441-177441
Closed Access
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Steven E. Nissen, Wei Ni, Xi Shen, et al.
New England Journal of Medicine (2025)
Closed Access
Key Concepts in Cardiovascular Secondary Prevention: A Case-Based Review
Shruti Revankar, Nezar Shakra, J. Michael DiMaio, et al.
The American Journal of Cardiology (2025)
Closed Access
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Antonio Greco, Simone Finocchiaro, Marco Spagnolo, et al.
Circulation (2025) Vol. 151, Iss. 6, pp. 400-415
Closed Access
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers
Robert S. Rosenson, J. Antonio G. López, Daniel Gaudet, et al.
JAMA Cardiology (2025)
Closed Access
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
Song Liu, Xingjin Wang, Jiaqiang Hu, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Lipoprotein(a) is a highly atherogenic lipoprotein: pathophysiological basis and clinical implications
Elias Björnson, Martin Adiels, Jan Borén, et al.
Current Opinion in Cardiology (2024) Vol. 39, Iss. 6, pp. 503-510
Closed Access | Times Cited: 3
The Role of Lipoprotein(a) in Peripheral Artery Disease
Nicholas Pavlatos, Dinesh Kalra
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1229-1229
Open Access | Times Cited: 2
Metabolic Syndrome and Pharmacological Interventions in Clinical Development
Eugen Javor, David Šarčević, Arnes Rešić
Diabetology (2024) Vol. 5, Iss. 3, pp. 300-320
Open Access | Times Cited: 2
Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across hs-CRP
Pamela L. Alebna, Chao Han, Mariateresa Ambrosio, et al.
JACC Advances (2024) Vol. 3, Iss. 12, pp. 101409-101409
Closed Access | Times Cited: 2
A journey into siRNA therapeutics development: A focus on Pharmacokinetics and Pharmacodynamics
Go-Wun Choi, Ju Hee Kim, Dong‐Wook Kang, et al.
European Journal of Pharmaceutical Sciences (2024) Vol. 205, pp. 106981-106981
Open Access | Times Cited: 2
Development, Opportunities and Challenges of siRNA Nucleic Acid Drugs
Bowen Xiao, Shaopeng Wang, Yu Pan, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 36, Iss. 1, pp. 102437-102437
Open Access | Times Cited: 2
Lipoprotein (a) testing patterns among subjects with a measured lipid panel: the Mayo Clinic experience
Matteo Manzato, Jeffrey W. Meeusen, Leslie J. Donato, et al.
American Journal of Preventive Cardiology (2024) Vol. 20, pp. 100886-100886
Open Access | Times Cited: 1
The functions of apolipoproteins and lipoproteins in health and disease
Zijun Ma, Jixin Zhong, Wei Tu, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 1
Lipoprotein (a): Underrecognized Risk with a Promising Future
Matteo Manzato, R. Scott Wright, Allan S. Jaffe, et al.
Reviews in Cardiovascular Medicine (2024) Vol. 25, Iss. 11
Open Access | Times Cited: 1
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Brian Tomlinson
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs
Aleksandra Krzesińska, Joanna Marlęga-Linert, Gabriela Chyła-Danił, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13597-13597
Open Access
The era of targeted therapy for hyperlipidemia
У.В. Чубыкина, A. V. Tyurina, М. В. Ежов
Russian Journal of Cardiology (2024) Vol. 29, Iss. 8, pp. 6038-6038
Open Access
Page 1 - Next Page

Scroll to top